TRANSGENE EXPRESSION IN AVIANS
A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
1 - 25 . (canceled)
26 . A method of using a transgenic chicken to produce an exogenous protein comprising:
providing a transgenic chicken,
wherein the transgenic chicken contains in its genome an exogenous nucleotide sequence comprising (i) an ovalbumin promoter operably linked to an exogenous coding region encoding an exogenous protein and (ii) a self-inactivating avian leukosis viral (ALV) vector comprising a 5′ long terminal repeat that comprises a nucleic acid at least 90% identical to nucleotides 174-346 SEQ ID NO:29,
wherein the transgenic chicken makes the exogenous protein in a hard shell egg laid by the chicken.
27 . A method of using a transgenic chicken to produce an exogenous protein comprising:
providing a transgenic chicken,
wherein the transgenic chicken contains in its genome an exogenous nucleotide sequence comprising (i) an oviduct specific promoter operably linked to an exogenous coding region encoding an exogenous protein and (ii) a self-inactivating avian leukosis viral (ALV) vector comprising a 5′ long terminal repeat that comprises a nucleic acid at least 90% identical to nucleotides 174-346 SEQ ID NO:29,
wherein the transgenic chicken makes the exogenous protein in a hard shell egg laid by the chicken,
wherein the oviduct specific promoter comprises a nucleic acid at least 90% identical to a nucleic acid molecule that comprises from 5′ to 3′ the ovalbumin Dnase hypersensitive site (DHS) III, 5′ UTR-3′ portion of Exon 1, and 3′ UTR;
wherein
the 5′ UTR-3′ portion from Exon 1 is the nucleotide sequence 8295 through 8311 of SEQ ID NO: 22;
the 3′ UTR is the nucleotide sequence 13576 through 14209 of SEQ ID NO: 22; and
the DHS III is the nucleotide sequence 3253 through 3559 of SEQ ID NO: 22.
28 . The method of claim 26 wherein the 5′ long terminal repeat that comprises a nucleic acid at least 95% identical to nucleotides 174-346 SEQ ID NO:29.
29 . The method of claim 27 wherein the 5′ long terminal repeat that comprises a nucleic acid at least 95% identical to nucleotides 174-346 SEQ ID NO:29.
30 . The method of claim 26 wherein the exogenous nucleotide further comprises a nucleotide sequence for antibiotic resistance that is not operably linked to a functional promoter and the self-inactivating ALV vector is also a SC negative vector.
31 . The method of claim 27 wherein the exogenous nucleotide further comprises a nucleotide sequence for antibiotic resistance that is not operably linked to a functional promoter and the self-inactivating ALV vector is also a SC negative vector.